Cargando…

Multiphysics pharmacokinetic model for targeted nanoparticles

Nanoparticles (NP) are being increasingly explored as vehicles for targeted drug delivery because they can overcome free therapeutic limitations by drug encapsulation, thereby increasing solubility and transport across cell membranes. However, a translational gap exists from animal to human studies...

Descripción completa

Detalles Bibliográficos
Autores principales: Glass, Emma M., Kulkarni, Sahil, Eng, Christina, Feng, Shurui, Malaviya, Avishi, Radhakrishnan, Ravi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335923/
https://www.ncbi.nlm.nih.gov/pubmed/35909883
http://dx.doi.org/10.3389/fmedt.2022.934015
_version_ 1784759438493614080
author Glass, Emma M.
Kulkarni, Sahil
Eng, Christina
Feng, Shurui
Malaviya, Avishi
Radhakrishnan, Ravi
author_facet Glass, Emma M.
Kulkarni, Sahil
Eng, Christina
Feng, Shurui
Malaviya, Avishi
Radhakrishnan, Ravi
author_sort Glass, Emma M.
collection PubMed
description Nanoparticles (NP) are being increasingly explored as vehicles for targeted drug delivery because they can overcome free therapeutic limitations by drug encapsulation, thereby increasing solubility and transport across cell membranes. However, a translational gap exists from animal to human studies resulting in only several NP having FDA approval. Because of this, researchers have begun to turn toward physiologically based pharmacokinetic (PBPK) models to guide in vivo NP experimentation. However, typical PBPK models use an empirically derived framework that cannot be universally applied to varying NP constructs and experimental settings. The purpose of this study was to develop a physics-based multiscale PBPK compartmental model for determining continuous NP biodistribution. We successfully developed two versions of a physics-based compartmental model, models A and B, and validated the models with experimental data. The more physiologically relevant model (model B) had an output that more closely resembled experimental data as determined by normalized root mean squared deviation (NRMSD) analysis. A branched model was developed to enable the model to account for varying NP sizes. With the help of the branched model, we were able to show that branching in vasculature causes enhanced uptake of NP in the organ tissue. The models were solved using two of the most popular computational platforms, MATLAB and Julia. Our experimentation with the two suggests the highly optimized ODE solver package DifferentialEquations.jl in Julia outperforms MATLAB when solving a stiff system of ordinary differential equations (ODEs). We experimented with solving our PBPK model with a neural network using Julia's Flux.jl package. We were able to demonstrate that a neural network can learn to solve a system of ODEs when the system can be made non-stiff via quasi-steady-state approximation (QSSA). Our model incorporates modules that account for varying NP surface chemistries, multiscale vascular hydrodynamic effects, and effects of the immune system to create a more comprehensive and modular model for predicting NP biodistribution in a variety of NP constructs.
format Online
Article
Text
id pubmed-9335923
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93359232022-07-30 Multiphysics pharmacokinetic model for targeted nanoparticles Glass, Emma M. Kulkarni, Sahil Eng, Christina Feng, Shurui Malaviya, Avishi Radhakrishnan, Ravi Front Med Technol Medical Technology Nanoparticles (NP) are being increasingly explored as vehicles for targeted drug delivery because they can overcome free therapeutic limitations by drug encapsulation, thereby increasing solubility and transport across cell membranes. However, a translational gap exists from animal to human studies resulting in only several NP having FDA approval. Because of this, researchers have begun to turn toward physiologically based pharmacokinetic (PBPK) models to guide in vivo NP experimentation. However, typical PBPK models use an empirically derived framework that cannot be universally applied to varying NP constructs and experimental settings. The purpose of this study was to develop a physics-based multiscale PBPK compartmental model for determining continuous NP biodistribution. We successfully developed two versions of a physics-based compartmental model, models A and B, and validated the models with experimental data. The more physiologically relevant model (model B) had an output that more closely resembled experimental data as determined by normalized root mean squared deviation (NRMSD) analysis. A branched model was developed to enable the model to account for varying NP sizes. With the help of the branched model, we were able to show that branching in vasculature causes enhanced uptake of NP in the organ tissue. The models were solved using two of the most popular computational platforms, MATLAB and Julia. Our experimentation with the two suggests the highly optimized ODE solver package DifferentialEquations.jl in Julia outperforms MATLAB when solving a stiff system of ordinary differential equations (ODEs). We experimented with solving our PBPK model with a neural network using Julia's Flux.jl package. We were able to demonstrate that a neural network can learn to solve a system of ODEs when the system can be made non-stiff via quasi-steady-state approximation (QSSA). Our model incorporates modules that account for varying NP surface chemistries, multiscale vascular hydrodynamic effects, and effects of the immune system to create a more comprehensive and modular model for predicting NP biodistribution in a variety of NP constructs. Frontiers Media S.A. 2022-07-15 /pmc/articles/PMC9335923/ /pubmed/35909883 http://dx.doi.org/10.3389/fmedt.2022.934015 Text en Copyright © 2022 Glass, Kulkarni, Eng, Feng, Malaviya and Radhakrishnan. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medical Technology
Glass, Emma M.
Kulkarni, Sahil
Eng, Christina
Feng, Shurui
Malaviya, Avishi
Radhakrishnan, Ravi
Multiphysics pharmacokinetic model for targeted nanoparticles
title Multiphysics pharmacokinetic model for targeted nanoparticles
title_full Multiphysics pharmacokinetic model for targeted nanoparticles
title_fullStr Multiphysics pharmacokinetic model for targeted nanoparticles
title_full_unstemmed Multiphysics pharmacokinetic model for targeted nanoparticles
title_short Multiphysics pharmacokinetic model for targeted nanoparticles
title_sort multiphysics pharmacokinetic model for targeted nanoparticles
topic Medical Technology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9335923/
https://www.ncbi.nlm.nih.gov/pubmed/35909883
http://dx.doi.org/10.3389/fmedt.2022.934015
work_keys_str_mv AT glassemmam multiphysicspharmacokineticmodelfortargetednanoparticles
AT kulkarnisahil multiphysicspharmacokineticmodelfortargetednanoparticles
AT engchristina multiphysicspharmacokineticmodelfortargetednanoparticles
AT fengshurui multiphysicspharmacokineticmodelfortargetednanoparticles
AT malaviyaavishi multiphysicspharmacokineticmodelfortargetednanoparticles
AT radhakrishnanravi multiphysicspharmacokineticmodelfortargetednanoparticles